Nevertheless, there are evidence that pancreatic cancer cells with EGFR high expression were sensitive to nimotuzumab treatment in vivo [31] and results for EGFR-overexpression just reach statistical significance in the German clinical trial [17]. The gene discussed is EGFR; the disease is pancreatic neoplasm.